Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare Progression Free Survival (PFS) using RECIST 1.1 as assessed by (Blinded Independent Central Review) BICR and Overall Survival (OS) in PD-L1 positive subjects and all subjects with advanced or metastatic urothelial carcinoma treated with: (a) Pembrolizumab + chemotherapy versus chemotherapy (b) Pembrolizumab versus chemotherapy
Critère d'inclusion
- Advanced or Metastatic Urothelial Carcinoma